NEW YORK(GenomeWeb) – The US Patent and Trademark Office Patent Trial and Appeal Board has nullified 13 claims of a patent held by Illumina that is at the center of litigation filed by the company against Ariosa Diagnostics alleging patent infringement. 

On Wednesday, the USPTO board nullified claims 1-13 of US Patent No. 8,296,076 after an inter partes review determined that Ariosa Diagnostics, which petitioned for the review, "demonstrated by a preponderance of the evidence that the challenged claims of the … patent are unpatentable." 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.